<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02730364</url>
  </required_header>
  <id_info>
    <org_study_id>205637</org_study_id>
    <nct_id>NCT02730364</nct_id>
  </id_info>
  <brief_title>An Efficacy and Safety Study of Theraflu Night Powder as Oral Solution for Cold and Flu</brief_title>
  <official_title>An Open-label, Multicenter, Randomized, Parallel Group, Single-dose Study to Assess the Short Term Efficacy and Safety of Paracetamol 500 mg + Phenylephrine HCl 10 mg + Pheniramine Maleate 20 mg + Vitamin C 200 mg Powder for Oral Solution in Subjects With Symptoms of an Upper Respiratory Tract Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the short term efficacy of the Theraflu Night powder
      for oral solution in the Russian population in &quot;Short term relief of the symptoms of colds,
      chills and influenza, including mild to moderate pain, fever and nasal congestion&quot;.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    The clinical phase of the study (from FSFV to LSLV) was never initiated due to the sponsor's
    decision.
  </why_stopped>
  <start_date type="Anticipated">February 1, 2017</start_date>
  <completion_date type="Anticipated">April 1, 2017</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>This was an open label study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy assessment Change from baseline, 3 hours after dosing in the Jackson Total Symptom Score (JTSS)</measure>
    <time_frame>At 3 hours post dosing</time_frame>
    <description>The severity of common cold symptoms will be self-assessed using the Jackson 8 items scale (questionnaire) by the participants on the site. This questionnaire measures the severity of 5 local symptoms (nasal congestion, rhinorrhea, sneezing, cough, and sore throat) and 3 systemic symptoms (chilliness, headache, malaise) each on a 4-point ordinal scale (0=not present, 1= mild, 2=moderate, 3= severe).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Infections, Respiratory Tract</condition>
  <arm_group>
    <arm_group_label>Theraflu night powder</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single dose (1 sachet) of Theraflu Night powder containing paracetamol, phenylephrine HCl, pheniramine maleate, and vitamin C as oral solution.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants in this arm will not receive any medication</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paracetamol, phenylephrine HCl, pheniramine maleate, and vitamin C</intervention_name>
    <description>One sachet is provided for each participant randomized to the Theraflu Night powder containing paracetamol, phenylephrine HCl, pheniramine maleate, and vitamin C as oral solution.</description>
    <arm_group_label>Theraflu night powder</arm_group_label>
    <other_name>Theraflu Night powder for oral solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants must understand and provide written informed consent before any
             assessment is performed, understand the study procedures, and be willing and able to
             complete the required assessments

          -  Males and females ≥ 18 years

          -  Clinical diagnosis of a URTI as diagnosed by the investigator

          -  Mild to moderate sore throat, i.e. rated as 1 or 2 on a 4-point ordinal scale (0=not
             present, 1= mild, 2=moderate, 3=severe), or headache (1, 2 or 3) or fever (less than
             39°C ) or/and Nasal congestion (blocked nose): may be accompanied by rhinorrhea (runny
             nose) and/or sneezing

          -  Baseline Jackson TSS &gt; 8

          -  Common cold symptoms for less than 48 hours

        Exclusion Criteria:

          -  Use of other investigational drugs within 30 days or 5 half-lives of enrollment,
             whichever is longer. Investigational drug refers to any drug being evaluated in
             clinical trials

          -  History of or known hypersensitivity to any of the study drugs, excipients or to drugs
             of similar chemical classes

          -  Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a
             female after conception and until the termination of gestation, confirmed by a
             positive hCG laboratory test (&gt; 5 mIU/mL) or urine dipstick at baseline

          -  Any history of drug hypersensitivity, asthma, urticaria, or other significant allergic
             diathesis. Participants with uncomplicated seasonal allergic rhinitis can be accepted
             if expected allergy season is clearly one month outside enrollment/ treatment period

          -  Any history of brain diseases, liver diseases or epilepsy

          -  Any evidence of uncontrolled cardiovascular (including hypertension), pulmonary,
             renal, hepatic, gastrointestinal, hematological, endocrinological, metabolic,
             neurological or psychiatric diseases at screening

          -  Subject has closed angle glaucoma, urinary retention, prostatic hyperplasia,
             pyloroduodenal obstruction, pheochromocytoma, diabetes mellitus

          -  A positive alcohol breath test or positive urine drug screen or a medical history data
             indicative of alcoholism, drug addiction, or drug abuse within the preceding 2 years

          -  Subject is current smoker of ≥10 cigarettes per day (or reports equivalent smoking
             habits using other tobacco products) and is unwilling to refrain from smoking while at
             the study site

          -  Subject is current smoker of ≥10 cigarettes per day (or reports equivalent smoking
             habits using other tobacco products) and is unwilling to refrain from smoking while at
             the study site

          -  Subject is taking or has taken within the last two weeks of dosing monoamine oxidase
             inhibitors, antidepressants, atropine, beta-blocking or sympathomimetic drugs
             desferrioxamine, hepatotoxic drugs, drugs inducing liver microsomal enzyme, (such as
             phenytoin, carbamazepine, isoniazid and rifampicin), neuroleptic drugs, chlorzoxazone,
             CNS depressant drugs including barbiturates, hypnotics, opioid analgesics, anxiolytic
             sedatives, antipsychotics or is anticipated to require any of these medications at any
             time throughout the study

          -  Subject has used: Systemic or topical corticosteroids (with the exception of HRT and
             contraceptive steroids for females), within 3 weeks prior to dosing or Slow-release
             steroids (with the exception of HRT and contraceptive steroids for females) within 90
             days prior to dosing

          -  Subject has used any of the following medications within 6 hours before first study
             drug administration, or is anticipated to use any of these medications at any time
             throughout the study: Any inhaler, medicated confectionary, throat lozenges, throat
             pastilles, sprays, any products with demulcent properties such as chewing gums and
             boiled sweets or mints, Any medication for sore throat containing a local anaesthetic,
             Cold products and oral nasal decongestant products, Paracetamol or any NSAID

          -  Subject has used substances of abuse, herbal medicines, antihistamines and homeopathic
             medicine within 72 hours of dosing or is anticipated to require any of these drugs at
             any time throughout the study

          -  Subject was previously enrolled into the current study

          -  Persons directly or indirectly involved in the execution of this protocol, including
             first degree relative of a study investigator, employees of the clinical study site,
             employees of the CRO and persons related to them

          -  &quot;Vulnerable&quot; individual (as defined by the IRB e.g. incarcerated person)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 1, 2016</study_first_submitted>
  <study_first_submitted_qc>March 31, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2016</study_first_posted>
  <last_update_submitted>March 9, 2018</last_update_submitted>
  <last_update_submitted_qc>March 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Ascorbic Acid</mesh_term>
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Phenylephrine</mesh_term>
    <mesh_term>Oxymetazoline</mesh_term>
    <mesh_term>Maleic acid</mesh_term>
    <mesh_term>Pheniramine</mesh_term>
    <mesh_term>Dextromethorphan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

